"Unhealthy competition" part of Indian scenario
This article was originally published in Clinica
Local companies in India are continuing to be burdened by a health products procurement system that is said to be riddled with corruption. The majority of complaints about the system are directed at local government officials, but companies also suspect unethical undercutting from rivals.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.